Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

Graves’ disease occurs when the thyroid gland becomes overactive and produces more thyroid hormones. This may lead to other medical complications, including issues with your heart, bones ...

The active phase can last anywhere from 6 months to 2 years. Thyroid eye disease is most common in people with Graves' ...

What is Graves disease? In this condition, autoimmune antibodies are produced in the body which are similar to endogenous TSH (thyroid stimulating ... the muscles of the eye and thus, lead to ...

Key Features of Graves' Disease: - Goiter: An enlarged thyroid gland may appear as a noticeable swelling in the neck. - Eye Symptoms: A condition called Graves' ophthalmopathy affects some ...

We report herein a case of thyroid mucosa-associated lymphoid tissue (MALT) lymphoma in a patient receiving antithyroid drug therapy for Graves' disease. A 75-year-old woman first presented with ...

Topline results have been announced from a Phase 2/3 trial assessing linsitinib for the treatment of active, moderate to ...

Thyroid autoimmune diseases are among the most common organ specific autoimmune diseases. The most prevalent diagnoses are Graves’ disease and Hashimoto’s thyroiditis, which result in ...

Sling Therapeutics’ oral challenger to Amgen’s intravenous Tepezza has hit the mark in a phase 2b/3 thyroid eye disease (TED) ...

Kamuvudine-9 is under clinical development by Inflammasome Therapeutics and currently in Phase I for Graves' Ophthalmopathy.

COVID-19 vaccines were not associated with increased risk for thyroid diseases but were associated with increased risk for exacerbated hypothyroidism.